8-K: InMed Pharmaceuticals Amends At-the-Market Offering Agreement

InMed Pharmaceuticals has amended its At-the-Market Offering Agreement to update sales settlement provisions, reimbursement terms, and company representations.

Summary

• InMed Pharmaceuticals Inc. has amended its existing At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC.
• The amendment, dated June 27, 2024, updates the original agreement from April 7, 2022.
• Key changes include revisions to sales settlement procedures, reimbursement terms, and the representations made by InMed to the sales agent.
• The company may offer and sell common shares through the agent from time to time.
• The shares will be sold under a shelf registration statement initially filed on February 4, 2022, and declared effective on February 11, 2022.
• The amendment also includes updates to ensure compliance with data privacy laws and clarifies the terms of previous letter agreements.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a routine amendment to a financing agreement, which is expected for a company in this stage. There are no significant positive or negative surprises.

Positives

• The amendment allows InMed to continue to raise capital through at-the-market offerings.
• The updated terms provide clarity on settlement procedures and reimbursement.
• The inclusion of data privacy compliance demonstrates a commitment to regulatory standards.
• The clarification of previous letter agreements ensures continuity and enforceability.

Risks

• The company's reliance on at-the-market offerings may dilute existing shareholders.
• The need to comply with data privacy laws adds complexity and potential costs.
• The company's ability to sell shares under the agreement is subject to market conditions.

Future Outlook

The company will continue to offer and sell common shares through the agent under the amended agreement, subject to market conditions and regulatory requirements.

Management Comments

• Eric A. Adams, President & CEO, signed the amendment on behalf of InMed Pharmaceuticals Inc.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, allowing them to sell shares gradually into the market without significant price impact. This amendment is a routine update to an existing agreement.

Comparison to Industry Standards

• Many small-cap biotech companies use at-the-market offerings to raise capital, similar to InMed's approach.
• The terms of the agreement, such as settlement times and reimbursement, are generally consistent with industry standards for these types of offerings.
• The inclusion of data privacy compliance is becoming increasingly standard due to growing regulatory scrutiny.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's ability to raise capital through this agreement is beneficial for its operations.
• The updated data privacy compliance measures may impact customers and vendors.

Next Steps

• InMed will continue to offer and sell common shares through the agent.
• The company will need to comply with the updated terms of the agreement.
• The company will need to monitor market conditions for optimal share sales.

Key Dates

Keywords

At-the-Market Offering, ATM Agreement, Common Shares, H.C. Wainwright, Securities Offering, Data Privacy, Capital Raise, Settlement Provisions, Reimbursement Terms, Shelf Registration